Bioventix PLC
LSE:BVXP

Watchlist Manager
Bioventix PLC Logo
Bioventix PLC
LSE:BVXP
Watchlist
Price: 1 775 GBX -4.05% Market Closed
Market Cap: 92.7m GBX
Section:
 

Relative Value

The Relative Value of one BVXP stock under the Base Case scenario is 2 412.17 GBX. Compared to the current market price of 1 775 GBX, Bioventix PLC is Undervalued by 26%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

BVXP Relative Value
Base Case
2 412.17 GBX
Undervaluation 26%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

7.1
P/S
P/S
Price to Sales
7.1
vs History
98
vs Industry
43
Median 3Y
15.4
Median 5Y
15.5
Industry
8.2
Forward
7.3
More Details
12.2
P/E
P/E
Price to Earnings
12.2
vs History
98
vs Industry
8
Median 3Y
23.7
Median 5Y
24
Industry
24.2
Forward
12.9
More Details
13.2
P/OCF
P/OCF
Price to OCF
13.2
vs History
98
vs Industry
11
Median 3Y
24.8
Median 5Y
25
Industry
23
More Details
13.2
P/FCFE
P/FCFE
Price to FCFE
13.2
vs History
98
vs Industry
10
Median 3Y
24.8
Median 5Y
25.1
Industry
25.5
More Details
8
P/B
P/B
Price to Book Value
8
vs History
98
vs Industry
8
Median 3Y
16.4
Median 5Y
16.4
Industry
3.3
More Details
6.7
EV/S
EV/S
Enterprise Value to Sales
6.7
vs History
98
vs Industry
36
Median 3Y
15
Median 5Y
15
Industry
8.6
Forward
6.9
More Details
7.4
EV/GP
EV/GP
Enterprise Value to Gross Profit
7.4
vs History
98
vs Industry
37
Median 3Y
15.9
Median 5Y
16.1
Industry
10.5
More Details
8.6
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
8.6
vs History
98
vs Industry
10
Median 3Y
18.8
Median 5Y
18.9
Industry
6.1
Forward
9.1
More Details
8.7
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
8.7
vs History
98
vs Industry
10
Median 3Y
19.1
Median 5Y
19.2
Industry
6.6
Forward
9.2
More Details
12.5
EV/OCF
EV/OCF
Enterprise Value to OCF
12.5
vs History
98
vs Industry
11
Median 3Y
24.1
Median 5Y
24.2
Industry
8.8
More Details
12.5
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
12.5
vs History
98
vs Industry
8
Median 3Y
24.2
Median 5Y
24.4
Industry
6.8
More Details
13.5
EV/IC
EV/IC
Enterprise Value to IC
13.5
vs History
98
vs Industry
11
Median 3Y
30.8
Median 5Y
31.9
Industry
5.7
More Details

Multiples Across Competitors

BVXP Competitors Multiples
Bioventix PLC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
UK
Bioventix PLC
LSE:BVXP
92.7m GBP 7.1 12.2 8.6 8.7
IL
Can Fite Biopharma Ltd
TASE:CANF
154.4T ILS 56 284 545.2 -3 865 260.4 -3 793 003.7 -3 784 560.6
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 004 331.7 -161 617.5 -196 255.2 -194 015.7
US
Abbvie Inc
NYSE:ABBV
388.9B USD 6.5 165.6 16.1 22.8
US
Amgen Inc
NASDAQ:AMGN
175.1B USD 4.9 25 18.1 18.1
US
Gilead Sciences Inc
NASDAQ:GILD
152.3B USD 5.2 18.8 12.6 12.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
117B USD 10 31.8 23.4 24.4
US
Epizyme Inc
F:EPE
94.1B EUR 2 071.8 -528.7 -575.7 -560.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.9B USD 5.7 17.7 16.9 19.1
AU
CSL Ltd
ASX:CSL
84.8B AUD 3.7 19 12.8 16
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
48.9B USD 15.2 1 122.1 151.2 183.4
P/S Multiple
Revenue Growth P/S to Growth
UK
Bioventix PLC
LSE:BVXP
Average P/S: 8 208 273.4
7.1
N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
56 284 545.2
140%
402 032.5
FR
Pharnext SCA
OTC:PNEXF
34 004 331.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.5
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.2
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10
10%
1
US
E
Epizyme Inc
F:EPE
2 071.8
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.7
6%
0.9
AU
CSL Ltd
ASX:CSL
3.7
5%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
15.2
46%
0.3
P/E Multiple
Earnings Growth PEG
UK
Bioventix PLC
LSE:BVXP
Average P/E: 176.5
12.2
N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -3 865 260.4 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 617.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
165.6
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.8
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.8
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -528.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.7
10%
1.8
AU
CSL Ltd
ASX:CSL
19
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 122.1
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
UK
Bioventix PLC
LSE:BVXP
Average EV/EBITDA: 32.5
8.6
N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -3 793 003.7 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 255.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.1
14%
1.1
US
Amgen Inc
NASDAQ:AMGN
18.1
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.6
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.4
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -575.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.9
11%
1.5
AU
CSL Ltd
ASX:CSL
12.8
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
151.2
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
UK
Bioventix PLC
LSE:BVXP
Average EV/EBIT: 38.1
8.7
N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -3 784 560.6 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 015.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.8
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.1
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.6
12%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.4
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -560.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.1
13%
1.5
AU
CSL Ltd
ASX:CSL
16
11%
1.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
183.4
N/A N/A

See Also

Summary
BVXP intrinsic value, competitors valuation, and company profile.
DCF Valuation
BVXP stock valuation using Discount Cash Flow valuation method.
Relative Valuation
BVXP stock valuation using valuation multiples.
Wall Street Estimates
BVXP price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
BVXP stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 309,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.